AGA Abstracts
250 - Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study

https://doi.org/10.1016/S0016-5085(17)30573-5Get rights and content

References (0)

Cited by (0)

View full text